|
|
Post by robsacher on Aug 21, 2015 13:42:16 GMT -5
Look at this chart. Specifically, look at how many times and for how long MNKD was under $4 over the last two years. Count how many days MNKD was below $4 and how many days it was above $4. Now, ask yourself if you believe if anything has fundamentally changed that would prevent MNKD from rebounding once again. Remember, this is a two year chart and it includes a significant time period before FDA approval and partnership announcement with Sanofi. Do you think that the diabetic community have turned their backs on Afrezza? Or, do you believe that there are other issues which are simply slowing up prescription sales? Is this a permanent problem pointing to the eventual collapse of the company? Or, is this an issue related to the issues Sanofi must deal with in order to make the continuing launch of Afrezza an eventual success? The chart speaks for itself. This is why I firmly believe that MNKD is a buying opportunity. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Aug 22, 2015 15:02:56 GMT -5
Rob,
The issue with biotechnology companies is that it takes relatively little $ to suppress its stock price. Add to that naked short selling and borrowed shares to "hedge" notes, leads many to believe MannKind is going bust. I have been through this several times, most worked out in my favor with the exception of Dendreon.
If one has the mind-set of an investor, meaning one is buying a business with tremendous potential, you will be great. But if one is losing sleep over weekly script numbers, MannKind is not for you.
Looking forward to your next article.
|
|
|
|
Post by mssciguy on Aug 22, 2015 15:30:55 GMT -5
|
|
|
|
Post by dreamboatcruise on Aug 22, 2015 16:23:38 GMT -5
Thanks for sharing. That's great... a medical practice that actually seems to be promoting Afrezza (presuming they don't do this for every drug). They probably have more leeway in what they can say vs what SNY could say at Afrezza.com. |
|
|
|
Post by robsacher on Aug 22, 2015 16:52:19 GMT -5
Rob, The issue with biotechnology companies is that it takes relatively little $ to suppress its stock price. Add to that naked short selling and borrowed shares to "hedge" notes, leads many to believe MannKind is going bust. I have been through this several times, most worked out in my favor with the exception of Dendreon. If one has the mind-set of an investor, meaning one is buying a business with tremendous potential, you will be great. But if one is losing sleep over weekly script numbers, MannKind is not for you. Looking forward to your next article. I agree. $5 million dollars can move the p/s down about 10%. |
|
|
|
Post by kball on Aug 22, 2015 17:56:16 GMT -5
Thanks for sharing. That's great... a medical practice that actually seems to be promoting Afrezza (presuming they don't do this for every drug). They probably have more leeway in what they can say vs what SNY could say at Afrezza.com.Clearly with this sentence. Each dose is contained in a small cartridge that is designed to be inhaled either before a meal or soon after the patient starts to eat. |
|
|
|
Post by beardawg on Aug 22, 2015 20:04:07 GMT -5
Thanks for sharing. That's great... a medical practice that actually seems to be promoting Afrezza (presuming they don't do this for every drug). They probably have more leeway in what they can say vs what SNY could say at Afrezza.com.Clearly with this sentence. Each dose is contained in a small cartridge that is designed to be inhaled either before a meal or soon after the patient starts to eat. That's the kind of thing Sanofi wants to get out, by educating the Key Opinion Leaders first. Since it can't come from Sanofi, let the KOLs figure it out first (with a few hints), then let them be the ones to tell the actual usage to the rest of the world. Once that happens, they later be able to actually add it to the label. |
|
|
|
Post by newmnkdinvestor on Aug 22, 2015 23:12:15 GMT -5
Wow they have glowing reviews also
|
|
|
|
Post by bretzyboy on Aug 23, 2015 8:02:26 GMT -5
Selling the September 3.50 put would return 3.14% net at expiration. If exercised the cost basis would be $3.39. Just another way to look at a possible rebound in share price.
|
|
|
|
Post by robsacher on Aug 23, 2015 9:58:51 GMT -5
Selling the September 3.50 put would return 3.14% net at expiration. If exercised the cost basis would be $3.39. Just another way to look at a possible rebound in share price. Yes, there is more than one way to profit on MNKD rebounds. I always recommend keeping a core position and buying when the stock sells off and selling all or part of that added position on the rebound. Look at the chart and pick your own entry and release positions. The chart shows that over the last two years, entry at $4.82 and release at $6.60, would have brought substantial profits, four times. We may be trading in a lower range now and until MannKind gets some decent script numbers, perhaps $4 and $5. Still, that $1 range represents a 25% gain. Look at the chart. There has only been one other time when MNKD traded below $4 in the last two years. And, look at how fast the rebound took place. Between 5/14 and 6/8, MNKD went from $3.63 to $7.23, almost doubling in value, a 98% return in around four weeks. finance.yahoo.com/echarts?s=MNKD+Interactive#{"range":"2y","allowChartStacking":true} I would not be shorting MNKD now. And, it looks, to me, that the chart says to buy. |
|
|
|
Post by mnholdem on Aug 23, 2015 10:30:34 GMT -5
You may be right about an imminent rebound but we all know the disclaimer, "Past results do not guaranty future..." Many are also claiming that the market as a whole has just turned and is now, officially, a bear market. Looking at the performance of my biotech holdings and stocks on watch over the past month seems to support the claim. I'm not about to ignore that, but there are other indicators besides the MNKD chart that are suggesting that an inflection point is near.
I, for one, am not entirely convinced that when Matt Pfeffer stated a few months ago that he expected share price to be much better in August, that he was referring to resolution of the debt. We have a number of trading days left in August, so we'll see if Matt was giving us a hint, as I suspect he was (I'm on record with that belief) of something else.
Regardless, since I am not a day trader, and I agree with Nate Pile that MNKD is a once in a lifetime stock, every day of accumulating at these levels is a good buy. Some may wait longer, thinking share price may drop as low as $3, but I'm not too concerned with hitting the exact bottom. One single announcement could make even $5-$7 per share a thing of the past. Greed can make people hold too long, but it can also cause them to wait too long for an excellent entry point and miss the bus.
Up or down, I am continuing to accumulate MNKD, but I'm also keeping some dry powder reserved for the unexpected.
Good fortune all.
|
|
|
|
Post by trenddiver on Aug 24, 2015 0:38:28 GMT -5
You may be right about an imminent rebound but we all know the disclaimer, "Past results do not guaranty future..." Many are also claiming that the market as a whole has just turned and is now, officially, a bear market. Looking at the performance of my biotech holdings and stocks on watch over the past month seems to support the claim. I'm not about to ignore that, but there are other indicators besides the MNKD chart that are suggesting that an inflection point is near. I, for one, am not entirely convinced that when Matt Pfeffer stated a few months ago that he expected share price to be much better in August, that he was referring to resolution of the debt. We have a number of trading days left in August, so we'll see if Matt was giving us a hint, as I suspect he was (I'm on record with that belief) of something else. Regardless, since I am not a day trader, and I agree with Nate Pile that MNKD is a once in a lifetime stock, every day of accumulating at these levels is a good buy. Some may wait longer, thinking share price may drop as low as $3, but I'm not too concerned with hitting the exact bottom. One single announcement could make even $5-$7 per share a thing of the past. Greed can make people hold too long, but it can also cause them to wait too long for an excellent entry point and miss the bus. Up or down, I am continuing to accumulate MNKD, but I'm also keeping some dry powder reserved for the unexpected. Good fortune all. Stop deluding yourself. Matt Pfeffer has as much information and knowledge about the future stock price as "the man in the moon". As Cramer once said speaking about The Fed, "They know nothing!!! |
|
|
|
Post by mbseeking on Aug 24, 2015 1:40:10 GMT -5
My gut, and not much else, tells me you may be right. There is no evidence yet Afrezza has failed (which would be necessary to fully justify the huge short interest) , but the script growth is also well below what we need for 'blockbuster' status: which I suspect underwrites many of our long theses. Until, if, one of these scenarios materializes, it may well be MNKD is destined to oscillate between teh longs and the shorts.
|
|
|
|
Post by newmnkdinvestor on Aug 24, 2015 9:44:06 GMT -5
I was down so much this am (but am sitting on a decent amount of cash for this moment )but got so shook and missed out on some great opportunity. Not only on MNKD but so many other sotcks. What a crazy morning. Almost a full reversal
|
|
